Voters face Proposition 38 on the November 2026 ballot, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute and the rest allocated via competitive grants focused on cancer, heart disease, and Alzheimer’s. The measure carries an estimated $500 million to $600 million annual General Fund repayment cost over roughly 20 years, prompting trader caution amid competing state priorities and limited bonding capacity. Support from disease advocacy organizations and arguments for offsetting federal research reductions create counterbalancing momentum, while concerns over debt service, administrative structure, and the suitability of bond financing for research sustain the narrow edge for rejection. Upcoming campaign activity, polling shifts, and any new federal funding developments before election day could alter the current trader consensus reflected in the 51.5% probability for “No.”